Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10300MR)

This product GTTS-WQ10300MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10300MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1834MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8671MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ13924MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ12883MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15315MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ998MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ12347MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ4217MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW